Transient and fully reversible leukocytosis in a myelodysplastic syndrome patient upon initiation of azacitidine treatment

Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R (2005) FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 10(3):176–182

Buckstein R, Yee K, Wells RA (2011) 5-azacytidine in myelodysplastic syndromes: a clinical practice guideline. Cancer Treat Rev 37(2):160–167

San Miguel Amigo L, Franco Osorio R, Mercadal Vilchez S, Martinez-Frances A (2011) Azacitidine adverse effects in patients with myelodysplastic syndromes. Adv Ther 28(Suppl 4):6–11

Santini V, Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Silverman LR, List A, Gore SD, Seymour JF, Backstrom J, Beach CL (2010) Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Eur J Haematol 85(2):130–138

Platzbecker U, Aul C, Ehninger G, Giagounidis A (2010) Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil. Ann Hematol 89(4):427–428

Issa JP, Kantarjian HM, Kirkpatrick P (2005) Azacitidine. Nat Rev Drug Discov 4(4):275–276

Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome—biological and translational implications. Nat Rev Cancer 11(10):726–734

Tsai HC, Baylin SB (2011) Cancer epigenetics: linking basic biology to clinical medicine. Cell Res 21(3):502–517